At a glance
A Semax-related experimental compound with important evidence gaps.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Cognition and neuronal resilience are research themes in the cited material. Check whether each experiment actually tested Adamax or another peptide.[4][7][8]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Adamax.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 300 µg (0.3 mg) | 9 units (0.09 mL) |
| Weeks 3–4 | 500 µg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 5–6 | 750 µg (0.75 mg) | 23 units (0.23 mL) |
| Weeks 7–8 | 1000 µg (1.0 mg) | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units readable. For the 300 µg starting dose (9 units = 0.09 mL), consider using 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support cognitive enhancement, neuroprotection, and neuroplasticity via BDNF upregulation[4][5].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired), followed by an equal off‑cycle period.
- Dose Range: 300–1000 µg daily with gradual titration (500 µg is typical mid‑range).
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 300 µg daily for 2 weeks (Week 1–2); allows adaptation to peptide effects.
- Increase: 500 µg daily (Week 3–4), then 750 µg (Week 5–6).
- Maintenance: 1000 µg daily (Week 7+) for continued nootropic support.
- Frequency: Once per day (subcutaneous), preferably morning for consistency.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks with careful monitoring.
- Off‑Cycle: Equal duration break (e.g., 8 weeks on, 8 weeks off) to prevent tolerance.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming.
- Gently swirl or roll the vial until powder fully dissolves (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality and potency.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; keep in original packaging to minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks for optimal potency.
- Avoid Freeze–Thaw: Do not refreeze reconstituted solution; freeze–thaw cycles denature peptides.
- Allow lyophilized vials to reach room temperature before opening to reduce condensation.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[10][10].
- Clean the vial stopper with an alcohol swab and allow to dry (~10 seconds).
- Draw the calculated dose into a sterile insulin syringe; remove air bubbles by gently tapping the syringe.
- Clean the injection site (abdomen, thigh, or upper arm) with a fresh alcohol swab; allow to dry.
- Pinch a fold of skin (~1 inch) between thumb and forefinger to elevate subcutaneous tissue.
- Insert the needle at 45–90° into the skinfold[10]; inject slowly and steadily (do not aspirate).
- Withdraw the needle and apply gentle pressure with a clean gauze pad; do not massage the site aggressively.
- Rotate injection sites systematically to prevent lipohypertrophy and ensure consistent absorption[11].
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Adamax, 10 mg each):
- 8 weeks (gradual dosing): 4 vials (total ~35.7 mg used)
- 12 weeks (gradual dosing): 7 vials (total ~60.2 mg used)
- 16 weeks (gradual dosing): 9 vials (total ~88.2 mg used)
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Note: For Week 1–2 dosing (9 units), consider 30‑unit or 50‑unit syringes for easier measurement precision.
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- 16 weeks (9 vials): 27 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
PubMed — Semax: structure, mechanism, and therapeutic potential (ACTH analog overview) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
PMC (NCBI) — ACTH(4–10) analogs: neuroprotective and cognitive effects (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
Journal of Neurochemistry (2006) — Semax binds specific brain sites and increases BDNF protein in rat basal forebrain (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
PubMed — Semax effects on dopamine and serotonin neurotransmission (mood and cognition) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 08
Research publication
PubMed — Neuroprotective effects of Semax in cerebral ischemia models (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
PubMed — Clinical safety and tolerability of Semax in human studies (no major adverse effects) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Public health resource
MedlinePlus — Subcutaneous injections: patient instructions and technique overview (opens in a new tab)medlineplus.gov
Back to overview ↑ - 11
Public health resource
NCBI Bookshelf — Injection best practices: site rotation, aseptic technique, and administration protocols (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.